About this trial
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.
Patient Profile
Patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma
Where’s this trial being run?
University Hospital Waterford and Mater Misericordiae University Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | BRUIN CLL-322 |
|---|---|
| Number: | 20-21-44 |
| Full Title: | A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322) |
| Principal Investigator: | Dr Anne Fortune |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | LOXO |
| Recruitment Started: |
Global: 20-Sep-2021 Ireland: |
| Global Recruitment Target: | 600 patients |
|---|---|
| Ireland Recruitment Target: | 2 patients |